Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04256941
Title Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

estrogen-receptor positive breast cancer

progesterone-receptor positive breast cancer


Abemaciclib + Fulvestrant

Fulvestrant + Palbociclib

Letrozole + Palbociclib

Fulvestrant + Ribociclib

Abemaciclib + Letrozole

Anastrozole + Palbociclib

Anastrozole + Ribociclib

Letrozole + Ribociclib

Abemaciclib + Anastrozole

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.